LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
for Ulcerative Colitis (UC)
50 locations incl. Phoenix
Sponsor: Eli Lilly and Company
Sex: All·Age: 18 - 80
Code: NCT07415044·Phase 2·Recruiting·Listed Feb 2026
Sanford USD Medical Center
Clinical research site in Sioux Falls, South Dakota · 1305 W 18TH ST, SIOUX FALLS, SD 57105-0401 · (605) 333-1000
As of September 2026, 18 paid clinical trials are recruiting at Sanford USD Medical Center in Sioux Falls, South Dakota. Active studies at this site cover conditions such as Breast Neoplasms, Carcinoma, Non-Small Cell Lung and Cutaneous Squamous Cell Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
New trial at Sanford USD Medical Center? We'll email you when one opens.
Recruiting clinical trials at Sanford USD Medical Center (18)
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
for Untreated, Unresectable, or Metastatic Colorectal Cancer
44 locations incl. Tucson
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
for Breast Neoplasms
125 locations incl. Anchorage
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
for Triple-Negative Breast Cancer
82 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06393374·Phase 3·Recruiting·Listed May 2024
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
for Early Breast Cancer
83 locations incl. Birmingham
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 100
Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
for Crohn's Disease
71 locations incl. Sun City
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 16 - 80
Code: NCT06430801·Phase 3·Recruiting·Listed May 2024
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for Epithelial Ovarian Cancer
67 locations incl. Birmingham
Sponsor: AbbVie
Sex: Female·Age: 18+
Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for Diffuse Large B-Cell Lymphoma
47 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for Carcinoma, Non-Small Cell Lung
104 locations incl. Anchorage
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT04389632·Phase 1·Recruiting·Listed May 2020
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
for Non Small Cell Lung Cancer
44 locations incl. Little Rock
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
for Metastatic Non Small Cell Lung Cancer
21 locations incl. Gilbert
Sponsor: Iovance Biotherapeutics, Inc.
Sex: All·Age: 18 - 70
Code: NCT04614103·Phase 2·Recruiting·Listed Nov 2020
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
for Extensive-Stage Small Cell Lung Cancer
18 locations incl. Daphne
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT06646276·Phase 3·Recruiting·Listed Oct 2024
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
for Carcinoma, Non-Small-Cell Lung
6 locations incl. Lebanon
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT04165070·Phase 1, Phase 2·Recruiting·Listed Nov 2019
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
for Carcinoma, Non-Small-Cell Lung
6 locations incl. Lebanon
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT04165798·Recruiting·Listed Nov 2019
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
for Solid Tumours
9 locations incl. Irvine
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07160725·Phase 1, Phase 2·Recruiting·Listed Sep 2025
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
for Non-small Cell Lung Cancer
5 locations incl. Lexington
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06731907·Phase 2·Recruiting·Listed Dec 2024
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
for Endometrial Cancer
10 locations incl. New Haven
Sponsor: BioNTech SE
Sex: Female·Age: 18+
Code: NCT06340568·Phase 3·Recruiting·Listed Apr 2024
The Minimalist Trial-2
for HPV-Related Oropharynx Squamous Cell Carcinoma
3 locations incl. St Louis
Sponsor: Washington University School of Medicine
Sex: All·Age: 18+
Code: NCT06702033·Phase 2·Recruiting·Listed Nov 2024
Get new-trial alerts for Sanford USD Medical Center
We'll email you whenever a new clinical trial starts recruiting at this research site in Sioux Falls, SD. Unsubscribe anytime.
More research sites in Sioux Falls
- Sanford USD Medical Center - Sioux Falls (85 trials)
- Sanford Cancer Center Oncology Clinic (61 trials)
- Avera Cancer Institute (45 trials)
- Sanford Health (16 trials)
- Sanford Cancer Center (15 trials)
- North Central Heart (6 trials)
- Avera Cancer Institute- Research (6 trials)
- Circle Clinical Research (5 trials)
- Vance Thompson Vision (5 trials)
- Avera Research Institute (4 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in Sioux Falls, SD · South Dakota clinical trials